Breast, Breast Neoadjuvant
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
EA1181 is closed to accrual, effective October 19, 2023.
EA1181 ER-Negative Cohort is closed to accrual, effective May 25, 2023.
EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022.